|
Independent risk factors for MACE and death in the study population (multivariate analysis, A1A1 (n = 690), A1A2 (n = 248), A2A2 (n = 25)) |
||||||
| MACE * |
Death ** |
|||||
|
|
||||||
| RR |
95% CI |
p |
RR |
95% CI |
p |
|
|
|
||||||
| LVEF < 40% |
2.07 |
1.37–3.13 |
0.001 |
2.81 |
1.53–5.16 |
0.001 |
| Follow-up |
||||||
| Beta-blocker no/yes |
2.46 |
1.70–3.56 |
< 0.001 |
10.64 |
4.54–24.94 |
< 0.001 |
| ACE inhibitor no/yes |
2.63 |
1.65–4.18 |
< 0.001 |
8.91 |
2.74–28.98 |
< 0.001 |
|
* For MACE, Cox multivariable model included: hypercholesterolemia, coronary artery disease extent, LVEF, treatments during follow-up (statin and/or betablocker and/or ACE inhibitor), GP IIIa polymorphism. Other variables were not statistically significant in the univariate model. ** For death, Cox multivariable model included: age, hypercholesterolemia, past or current smoking, prior MI, family history of MI, coronary artery disease extent, LVEF, revascularisations during follow-up (PCI, CABG), treatment during follow-up (ACE inhibitor, betablocker, statin), GP IIIa polymorphism. Other variables were not statistically significant in the univariate model. ACE, angiotensin converting enzyme; CABG, coronary artery bypass graft; CI, confidence interval; LVEF, left ventricular ejection fraction; MACE, major adverse coronary event; MI, myocardial infarction; PCI, percutaneous coronary intervention; RR, relative risk. | ||||||
Le Hello et al. Thrombosis Journal 2007 5:19 doi:10.1186/1477-9560-5-19 |
||||||